{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-009260","form_type":"8-K","ticker":"DWTX","cik":"0001818844","company_name":"Dogwood Therapeutics, Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.825634+00:00","generated_at":"2026-06-15T04:37:51.479424+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Virios Therapeutics reports Q1 2023 net loss of $1.5M; FDA amenable to IMC-1 Phase 3 proposal","bullets":["Net loss $1.5M ($0.08 per share) vs $4.0M ($0.48) in Q1 2022; R&D expenses fell to $0.5M from $2.8M.","Cash $5.3M as of March 31, 2023; company expects runway into Q2 2024, but IMC-1 trials need additional funding.","FDA amenable to Phase 3 program for IMC-1 (famciclovir/celecoxib) for fibromyalgia, pending review of chronic toxicology reports submitted in May 2023.","Top-line results from exploratory Long-COVID study (valacyclovir/celecoxib) expected in June 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-009260","json":"https://secwatch.observer/filing/0001558370-23-009260.json","markdown":"https://secwatch.observer/filing/0001558370-23-009260.md","text":"https://secwatch.observer/filing/0001558370-23-009260.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818844/000155837023009260/0001558370-23-009260-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818844/000155837023009260/tmb-20230511x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:37:51.479424+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a60f6d93fbfae06842aa6be75a00bbb4ba9a7450","claim":"Dogwood Therapeutics, Inc. reported the first quarter ended March 31, 2023 results: net income Net loss for the first quarter of 2023 was $1.5 million, or $0.08 basic and diluted net loss per share, EPS $0.08 basic and diluted net loss per share.","evidence_excerpt":"Net loss for the first quarter of 2023 was $1.5 million, or $0.08 basic and diluted net loss per share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1818844/000155837023009260/0001558370-23-009260-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Net income","value":"Net loss for the first quarter of 2023 was $1.5 million, or $0.08 basic and diluted net loss per share"},{"label":"EPS","value":"$0.08 basic and diluted net loss per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}